Nutrabolt picks JPMorgan, Goldman Sachs, BofA for US IPO that could raise up to $1 billion

Corporate Action
โดย Reuters·Read original
Summary · why it matters

Nutrabolt, the energy drink and supplements company behind C4 and Bloom, has selected JPMorgan, Goldman Sachs and Bank of America to lead a US initial public offering that could raise up to $1 billion, according to four people familiar with the matter. The Austin, Texas-based company has not previously reported its IPO plans or bank selection. Nutrabolt sells products under the C4, XTEND and Cellucor brands and said in September it was on track to exceed $1 billion in annual consolidated revenue. In 2022, Keurig Dr Pepper took a 30% stake in Nutrabolt at a $2.88 billion equity valuation as part of a long-term sales and distribution agreement.

Impact on stocks 7

Consumer Staples▲ · 3 stocks
Keurig Dr Pepper Inc
KDP
▲ PositiveCapitalrelevance

Holds 30% stake in Nutrabolt; IPO could increase value of its investment.

Financials▲ · 2 stocks
Digital Finance & Tokenization▲ · 1 stocks
JPMorgan Chase & Co
JPM
▲ PositiveCapitalrelevance

Selected as underwriter for Nutrabolt's IPO, generating fee income.

Space Economy▲ · 1 stocks

Off-coverage companies 1

NutraboltPrivate▲ Positive
Capitalrelevance

Company is planning an IPO that could raise up to $1 billion.

© 2026 MarketDXNews